Which is better, SANOFICONR.BO or VRTX?

On the Buffett-Fit framework, Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) currently grades higher than VRTX — 78/100 (B grade) vs 64/100 (C). That said, "better" depends on which framework you trust — SANOFICONR.BO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; VRTX wins on none. The full pillar breakdown is on this page.

Should I buy SANOFICONR.BO or VRTX?

This page is an educational comparison, not investment advice. Both SANOFICONR.BO and VRTX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is SANOFICONR.BO better than VRTX for value investing?

On the Buffett-style value-investing framework, SANOFICONR.BO currently grades higher — 78/100 vs 64/100, a 14-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between SANOFICONR.BO and VRTX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). SANOFICONR.BO currently scores 78/100 (B grade); VRTX scores 64/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, SANOFICONR.BO or VRTX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. SANOFICONR.BO and VRTX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, SANOFICONR.BO or VRTX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are SANOFICONR.BO and VRTX both Healthcare stocks?

Yes — both Sanofi Consumer Healthcare India Limited (SANOFICONR.BO) and Vertex Pharmaceuticals Incorporated (VRTX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this SANOFICONR.BO vs VRTX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Sanofi Consumer Healthcare India Limited

SANOFICONR.BO$104.05BHealthcare Market cap, Sector

Vertex Pharmaceuticals

VRTX$125.65BHealthcare Market cap, Sector

Overall winner

Sanofi Consumer Healthcare India Limited

SANOFICONR.BO 70 VRTX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

SANOFICONR.BO7wins

0winsVRTX

Warren Buffett

78B

C64

Benjamin Graham

89A

C66

Philip Fisher

83B

B70

Peter Lynch

77B

C61

Joel Greenblatt

91A

D55

Charlie Munger

86A

C67

Terry Smith

85A

C65

Side-by-side metrics

Metric	SANOFICONR.BO	VRTX
Market cap	$104.05B	$125.65B Winner
P/E (TTM)	44.0x	26.2x Winner
EV/EBIT	31.7x	23.1x Winner
ROIC (TTM)	Winner: 59.15%	17.74%
Gross margin	68.13%	86.28% Winner
Net margin	27.35%	35.4% Winner
Revenue CAGR 5y	Winner: 27.01%	12.37%
EPS CAGR 5y	Winner: 20.67%	14.2%
Debt / Equity	Winner: 0.1x	0.1x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

SANOFICONR.BO leads on

ROIC (TTM)59.15%vs 17.74%+70%
Revenue CAGR 5y27.01%vs 12.37%+54%
Debt / Equity0.1xvs 0.1x+37%
EPS CAGR 5y20.67%vs 14.2%+31%

VRTX leads on

P/E (TTM)26.2xvs 44.0x+40%
EV/EBIT23.1xvs 31.7x+27%
Net margin35.4%vs 27.35%+23%
Gross margin86.28%vs 68.13%+21%

More like SANOFICONR.BO

SANOFICONR.BO vs 1681.HK SANOFICONR.BO vs SANOFICONR.NS SANOFICONR.BO vs PME.AX SANOFICONR.BO vs CAMX.ST

More like VRTX

VRTX vs 1681.HK VRTX vs SANOFICONR.NS VRTX vs PME.AX VRTX vs CAMX.ST

Read the full Buffett-Brain analysis for SANOFICONR.BO Read the full Buffett-Brain analysis for VRTX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Side-by-side metrics

Metric	SANOFICONR.BO	VRTX
Market cap	$104.05B	$125.65B Winner
P/E (TTM)	44.0x	26.2x Winner
EV/EBIT	31.7x	23.1x Winner
ROIC (TTM)	Winner: 59.15%	17.74%
Gross margin	68.13%	86.28% Winner
Net margin	27.35%	35.4% Winner
Revenue CAGR 5y	Winner: 27.01%	12.37%
EPS CAGR 5y	Winner: 20.67%	14.2%
Debt / Equity	Winner: 0.1x	0.1x
Dividend yield	-	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

SANOFICONR.BO leads on

ROIC (TTM)59.15%vs 17.74%+70%
Revenue CAGR 5y27.01%vs 12.37%+54%
Debt / Equity0.1xvs 0.1x+37%
EPS CAGR 5y20.67%vs 14.2%+31%

VRTX leads on

P/E (TTM)26.2xvs 44.0x+40%
EV/EBIT23.1xvs 31.7x+27%
Net margin35.4%vs 27.35%+23%
Gross margin86.28%vs 68.13%+21%